ReviewNanoscale advances2020
Nanoscale covalent organic frameworks as theranostic platforms for oncotherapy: synthesis, functionalization, and applications.
Review in Nanoscale advances, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Melamine-Based Porous Organic Frameworks as Adsorbent Materials for the Removal of Organic Dyes from Wastewater.Molecules (Basel, Switzerland) · 2026Article
- Advanced strategies of covalent organic framework nanomedicines in targeting and overcoming biological barriers.Asian journal of pharmaceutical sciences · 2025Review
- Catalyst-Driven Improvements in Conventional Methods for Imine-Linked Covalent Organic Frameworks.Molecules (Basel, Switzerland) · 2025Review
- Reprogramming Lung Redox Homeostasis by NIR Driven Ultra-Small Pd Loaded Covalent Organic Framework Inhibits NF-κB Pathway for Acute Lung Injury Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Nanocatalytic system releases overloaded zinc ions and ROS to induce Znproptosis and interrupt cell cycle through inhibiting Akt/mTOR pathway.Theranostics · 2025Review
- Chitosan capped-NLCs enhanced codelivery of gefitinib and simvastatin into MDR HCC: impact of compositions on cell death, JNK3, and Telomerase.Oncology research · 2025Article
- Therapeutic types and advantages of functionalized nanoparticles in inducing ferroptosis in cancer therapy.Annals of medicine · 2024Review
- Chitosan-enclosed SLN improved SV-induced hepatocellular cell carcinoma death by modulation of IQGAP gene expression, JNK, and HDAC activities.Molecular biology reports · 2024Article
- Covalent-Organic Framework-Based Materials in Theranostic Applications: Insights into Their Advantages and Challenges.ACS omega · 2024Review
- Comprehensive Insights and Advancements in Gel Catalysts for Electrochemical Energy Conversion.Gels (Basel, Switzerland) · 2024Review
- Guanidinium-based Integrated Peptide Dendrimers: Pioneer Nanocarrier in Cancer Therapy.Protein and peptide letters · 2024Review
- Tumor-derived covalent organic framework nanozymes for targeted chemo-photothermal combination therapy.iScience · 2023Article
- Recent Advances in Electrochemical Biosensors for Food Control.Micromachines · 2023Review
- Composite materials based on covalent organic frameworks for multiple advanced applications.Exploration (Beijing, China) · 2023Review
- Covalent organic framework nanomedicines: Biocompatibility for advanced nanocarriers and cancer theranostics applications.Bioactive materials · 2023Review
- A biodegradable covalent organic framework for synergistic tumor therapy.Chemical science · 2023Article
- Ultrathin Covalent Organic Framework Nanosheets/TiMolecules (Basel, Switzerland) · 2022Article
- A conjugated 2D covalent organic framework as a drug delivery vehicle towards triple negative breast cancer malignancy.Nanoscale advances · 2022Article
- β-Amyloid Targeting with Two-Dimensional Covalent Organic Frameworks: Multi-Scale In-Silico Dissection of Nano-Biointerface.Chembiochem : a European journal of chemical biology · 2021Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cancer nanomedicine is one of the most promising domains that has emerged in the continuing search for cancer diagnosis and treatment. The rapid development of nanomaterials and nanotechnology provide a vast array of materials for use in cancer nanomedicine. Among the various nanomaterials, covalent organic frameworks (COFs) are becoming an attractive class of upstarts owing to their high crystallinity, structural regularity, inherent porosity, extensive functionality, design flexibility, and good biocompatibility. In this comprehensive review, recent developments and key achievements of COFs are provided, including their structural design, synthesis methods, nanocrystallization, and functionalization strategies. Subsequently, a systematic overview of the potential oncotherapy applications achieved till date in the fast-growing field of COFs is provided with the aim to inspire further contributions and developments to this nascent but promising field. Finally, development opportunities, critical challenges, and some personal perspectives for COF-based cancer therapeutics are presented.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.